10-Q quarterly report · filed Nov 9, 2026

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 10-Q Quarterly Report

Short answer

Amneal Pharmaceuticals, Inc. (AMRX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $863M (up 10.0% year over year) with net income of −$22M.

Q3 2026 key financials · XBRL

Revenue
$863M
+10.0% YoY · +8.4% QoQ
Net income
−$22M
−1015.8% YoY · −137.6% QoQ
Operating margin
11.1%
Gross margin
38.7%
EPS (diluted)
−$0.08
−144.4% QoQ

Source: XBRL data from the Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 10-Q on SEC EDGAR. USD.

Amneal Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $862.7M, up 10.0% YoY from $784.5M
  • Gross margin 38.7% vs 34.9%; operating income $95.4M vs $70.3M
  • Specialty strongest: revenue $150.3M, up 20.0%; gross margin 69.2% vs 41.1%
  • AvKARE weakest: revenue $165.3M, down 16.7%; operating income $17.4M, down 35.7%
  • Operating cash flow $50.3M year-to-date vs $209.7M; Kashiv acquisition funding drove $476.7M net borrowings
  • Tariff uncertainty and potential future generic-drug tariffs could increase costs and pressure margins; 2026 capital expenditures estimated at $150.0M

Risk Factors

  • New acquisition risk: Kashiv integration and biosimilar execution following $421.0 million cash consideration and 28.9 million shares issued
  • Regulatory risk: proposed generic-drug tariffs could reach 100% after July 31, 2028 and 200% thereafter
  • Legal risk: $8.0 million government-investigation charge recognized during the quarter
  • Operational risk: severe rain temporarily suspended an India facility and caused $5.4 million property and inventory charges
  • Financial risk: Kashiv financing increased revolver borrowings to $180.0 million and added $350.0 million Term Loan Due 2032 borrowings

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Amneal Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.